carisbamate Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Carisbamate is an experimental anticonvulsant drug that was under development by Johnson & Johnson Pharmaceutical Research and Development but never marketed.   Wikipedia

Chemistry

  • SMILES: NC(=O)OC[C@@H](O)c1ccccc1Cl
  • InChIKey: OLBWFRRUHYQABZ-MRVPVSSYSA-N
  • Mol. Mass: 215.64
  • ALogP: 1.47
  • ChEMBL Molecule:
    carisbamate  
More Chemistry

Pharmacology

Alternative names

carisbamate | jnj-10234094 | rwj333369 | rwj 333369 | rwj-333369 | (s)-(1-2-chlorophenyl)-1,2-ethanediol 2-carbamate | s-2-o-carbamoyl-1-o-chlorophenyl-ethanol | ykp-509

Organizations (5)

Research & Development (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (16)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (16)


 

Alcoholism (Phase 1/Phase 2)

Diabetic Neuropathies (Phase 2)

Drug Resistant Epilepsy (Phase 2)

Epilepsies, Partial (Phase 3)

Epilepsy (Phase 3)

Epilepsy, Complex Partial (Phase 3)

Epilepsy, Partial, Motor (Phase 3)

Essential Tremor (Phase 2)

Healthy Volunteers (Phase 1)

Herpes Zoster (Phase 2)

Lennox Gastaut Syndrome (Phase 3)

Migraine Disorders (Phase 2)

Neuralgia (Phase 2)

Neuralgia, Postherpetic (Phase 2)

Seizures (Phase 3)

Substance-Related Disorders (Phase 1/Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 21
  • # of Trial Organizations: 5

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue